Akero (AKRO) Falls in Active Trading for June 22

Equities Staff  |

Akero Therapeutics Inc (NASDAQ:AKRO) stock was among today's market movers, finishing trading down 7.06% to $10.93 on June 22.

594,823 shares were traded today compared to the 30-day daily average of 501,819 shares.

The company's stock dropped 44.40% so far in 2022.

Akero shares have moved between $7.52 and $28.94 over the past twelve months.

For technical charts, analysis, and more on Akero visit the company profile.

About Akero Therapeutics Inc

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH. Akero is headquartered in South San Francisco.

To get more information on Akero Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Akero Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content